argenex SE $ARGX Shares Sold by Campbell & CO Investment Adviser LLC

Campbell & CO Investment Adviser LLC reduced its stake in shares of argenex SE (NASDAQ:ARGX) by 45.8% in the 3rd quarter, Holdings Channel reports. The fund owned 2,999 shares of the company’s stock after selling 2,536 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in argenex were worth $2,212,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently bought and sold shares of the company. Adage Capital Partners GP L.L.C. grew its stake in shares of argenex by 114.3% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 297,113 shares of the company’s stock worth $163,775,000 after purchasing an additional 158,476 shares during the period. Franklin Resources Inc. lifted its stake in shares of argenex by 103.9% in the 2nd quarter. Franklin Resources Inc. now owns 279,803 shares of the company’s stock valued at $154,233,000 after purchasing an additional 142,606 shares during the period. Balyasny Asset Management L.P. boosted its holdings in argenex by 826.6% during the second quarter. Balyasny Asset Management L.P. now owns 89,296 shares of the company’s stock worth $49,222,000 after buying an additional 79,659 shares in the last quarter. Hudson Bay Capital Management LP purchased a new stake in argenex during the second quarter worth $37,441,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in argenex by 244.6% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 87,414 shares of the company’s stock valued at $48,184,000 after buying an additional 62,044 shares during the period. 60.32% of the stock is owned by institutional investors and hedge funds.

argenex Trading Down 1.6%

NASDAQ:ARGX opened at $800.01 on Friday. The stock has a 50 day moving average of $867.10 and a two-hundred day moving average of $761.92. argenex SE has a 12 month low of $510.05 and a 12 month high of $934.62. The firm has a market cap of $49.26 billion, a P/E ratio of 34.35, a price-to-earnings-growth ratio of 0.52 and a beta of 0.38.

argenex (NASDAQ:ARGX) last released its earnings results on Thursday, October 30th. The company reported $4.40 earnings per share for the quarter, beating the consensus estimate of $4.37 by $0.03. argenex had a return on equity of 29.78% and a net margin of 41.58%.The business had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.07 billion. On average, research analysts forecast that argenex SE will post 3.13 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Wedbush reissued an “outperform” rating and set a $1,000.00 target price on shares of argenex in a research note on Wednesday. JPMorgan Chase & Co. upped their price target on argenex from $925.00 to $1,100.00 and gave the stock an “overweight” rating in a report on Monday, December 8th. TD Cowen raised their price objective on argenex from $800.00 to $1,146.00 and gave the company a “buy” rating in a report on Friday, October 31st. Baird R W cut argenex from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 18th. Finally, Piper Sandler upped their target price on argenex from $820.00 to $930.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $986.72.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.